Milani M, Pecora S
Alk-Abellò Medical Department, Lainate, Italy.
Eur Ann Allergy Clin Immunol. 2011 Aug;43(4):111-6.
We evaluated, by means of a multicentre, prospective observational trial, the severity in term of symptoms and symptomatic drugs use and the presence of asthma in subjects with tree or cypress or olive, or ragweed or parietaria allergy and we evaluated also the efficacy of a consecutive 2-year specific sublingual immunotherapy treatment.
Consecutive patients suffering of respiratory allergies (rhinoconjunctivitis and/or mild moderate asthma) due to one of the described allergens were enrolled During the specific relevant pollen seasons for each allergens nose and eye symptoms and medication scores (SS and MS) were evaluated Global score (GS) was calculated as the sum of SS and MS. An Asthma symptom score if present, were also, calculated A total of 162 patients were enrolled in 14 Italian Allergic Clinics .Patients were treated with the relevant specific sublingual immunotherapy (SLITOne, ALK) for two consecutive pollen seasons.
At baseline prevalence of allergies was the following: tree 18% (30 patients); ragweed 14% (23 patients); olive 7% (11 patients); cypress 7% (12 patients) and pellitory 53% (86 patients). At baseline asthma was detected in 65 patients (40%). Asthma was more common in poli-sensitive subjects in comparison with mono-sensitive (51% vs. 300/o). According to allergen type, asthma was present in 47% of pellitory allergic patients, in 45% of olive allergic subjects, in 38% of ragweed allergic patients, in 26% of tree allergic patients and only in 9% of cypress allergic subjects. In pellitory, olive and ragweed allergic patients the frequency of asthma was statistically significant (P=0.0055) higher in comparison with other groups. At baseline GS mean (SD) in the whole population was 17(7). GS during the following 2 consecutive seasons with SLIT treatment decreased significantly (P=0.0001) to 9 (5) and to 7 (5), respectively (a reduction of 59% in comparison with baseline). In patients with asthma the mean clinical score decreased significantly from baseline value of 2. 7 to 0.3 at the end of the observation period No serious adverse events were reported Local side effects, mainly oral itching, were reported by 14% of patients and were mild and transient in nature.
In this population pellitory, olive and ragweed allergies are associated with a more severe clinical picture in comparison with tree and cypress allergy. A two-year SLIT treatment was associated with a significant reduction in SS, MS, GS and asthma score in comparison with baseline. SLIT was also safe and well tolerated
我们通过一项多中心前瞻性观察性试验,评估了对树木、柏树、橄榄树、豚草或墙草过敏的受试者的症状严重程度、症状性药物使用情况以及哮喘的存在情况,并且还评估了连续两年特异性舌下免疫治疗的疗效。
纳入因上述过敏原之一而患有呼吸道过敏( rhinoconjunctivitis和/或轻度至中度哮喘)的连续患者。在每种过敏原的相关花粉季节,评估鼻和眼症状及用药评分(SS和MS)。计算总体评分(GS),即SS与MS之和。如有哮喘症状评分,也进行计算。共有162名患者在14家意大利过敏诊所入组。患者接受相关特异性舌下免疫治疗(SLITOne,ALK)连续两个花粉季节。
基线时过敏患病率如下:树木18%(30例患者);豚草14%(23例患者);橄榄树7%(11例患者);柏树7%(12例患者);墙草53%(86例患者)。基线时在65例患者(40%)中检测到哮喘。与单敏患者相比,哮喘在多敏患者中更常见(51%对30%)。根据过敏原类型,哮喘在53%的墙草过敏患者、45%的橄榄树过敏患者、38%的豚草过敏患者、26%的树木过敏患者中存在,而仅在9%的柏树过敏患者中存在。在墙草、橄榄树和豚草过敏患者中,哮喘的发生率与其他组相比有统计学意义的更高(P=0.0055)。基线时总体人群的GS平均值(标准差)为17(7)。在接下来连续两个季节接受SLIT治疗期间,GS显著降低(P=0.0001),分别降至9(5)和7(5)(与基线相比降低了59%)。在哮喘患者中,平均临床评分在观察期结束时从基线值2.7显著降至0.3。未报告严重不良事件。14%的患者报告有局部副作用,主要为口腔瘙痒,性质轻微且短暂。
在该人群中,与树木和柏树过敏相比,墙草、橄榄树和豚草过敏与更严重的临床表现相关。与基线相比,两年的SLIT治疗与SS、MS、GS和哮喘评分的显著降低相关。SLIT也是安全且耐受性良好的。